Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

288
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
288

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urgent Virtual Care: Impact on GP, Emergency, and Scheduled Care Pathways.

Irish medical journal·2026
Same author

Breeding for sustainability: Development of an index to reduce greenhouse gas in dairy cattle.

Animal : an international journal of animal bioscience·2025
Same author

Minors and consent.

British dental journal·2024
Same author

Implementing Faecal Immunochemical Testing in Primary Care.

Irish medical journal·2024
Same author

Development of a Artificial Intelligence Dental Anxiety Scale (AI -CDAS) For Children: Validation And Reliability.

Mymensingh medical journal : MMJ·2024
Same author

Prevalence and risk factors associated with undiagnosed hypertension among adults aged 15-49 years in India: insights from the National Family Health Survey (NFHS-5).

Public health·2024
Same journal

Microneedling with adipose MSC exosomes versus monotherapy for androgenetic alopecia.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Diabetes and melanoma: Impact on prognosis and healthcare costs.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Differential survival with adjuvant immunotherapy in stage III acral versus non-acral melanoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Estimating the global burden of mental health disorders associated with atopic dermatitis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same journal

Correction to 'Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years'.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
See all related articles

Related Experiment Video

Updated: Feb 15, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Biosimilars: what the dermatologist should know.

P Yamauchi1, J Crowley2, P Kaur3

  • 1UCLA School of Medicine, Santa Monica, CA, USA.

Journal of the European Academy of Dermatology and Venereology : JEADV
|January 24, 2018
PubMed
Summary
This summary is machine-generated.

Biosimilars are highly similar biologic medicines, not identical copies. Demonstrating no clinically meaningful differences in safety or efficacy is key for their approval and use.

More Related Videos

Identification of Fatty Acids in Bacillus cereus
08:41

Identification of Fatty Acids in Bacillus cereus

Published on: December 5, 2016

10.1K
Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes
07:38

Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes

Published on: September 1, 2020

5.7K

Related Experiment Videos

Last Updated: Feb 15, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Identification of Fatty Acids in Bacillus cereus
08:41

Identification of Fatty Acids in Bacillus cereus

Published on: December 5, 2016

10.1K
Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes
07:38

Enabling Real-Time Compensation in Fast Photochemical Oxidations of Proteins for the Determination of Protein Topography Changes

Published on: September 1, 2020

5.7K

Area of Science:

  • Biopharmaceutical science
  • Pharmacology
  • Clinical medicine

Background:

  • Biosimilars are highly similar to approved biologic medicines but are not identical.
  • Unlike generics, biosimilars are unique molecules with minor acceptable differences from reference products.
  • Originator biologics can also undergo changes over time due to production alterations.

Purpose of the Study:

  • To review the current knowledge on biosimilars.
  • To provide clinicians with practical guidance on biosimilar use in dermatology.
  • To highlight the benefits of biosimilars in treating dermatologic diseases.

Main Methods:

  • Utilizing a 'totality of evidence' approach for biosimilar development.
  • Conducting comprehensive structural, functional, pharmacologic, and clinical assessments for similarity.
  • Designing phase 3 clinical trials to demonstrate no clinically meaningful differences compared to reference products.

Main Results:

  • Minor structural/functional differences are acceptable if they don't impact safety or efficacy.
  • Phase 3 trials aim to prove clinical similarity, not establish new efficacy.
  • Extrapolation of results to other indications requires scientific justification, including similar mechanisms of action.

Conclusions:

  • Biosimilars require a rigorous, stepwise development process.
  • Clinical trial design is critical for demonstrating biosimilarity.
  • Understanding biosimilars is essential for their appropriate clinical application, particularly in dermatology.